2015
Genomic Analysis Reveals That Immune Function Genes Are Strongly Linked to Clinical Outcome in the North Central Cancer Treatment Group N9831 Adjuvant Trastuzumab Trial
Perez EA, Thompson EA, Ballman KV, Anderson SK, Asmann YW, Kalari KR, Eckel-Passow JE, Dueck AC, Tenner KS, Jen J, Fan JB, Geiger XJ, McCullough AE, Chen B, Jenkins RB, Sledge GW, Winer EP, Gralow JR, Reinholz MM. Genomic Analysis Reveals That Immune Function Genes Are Strongly Linked to Clinical Outcome in the North Central Cancer Treatment Group N9831 Adjuvant Trastuzumab Trial. Journal Of Clinical Oncology 2015, 33: 701-708. PMID: 25605861, PMCID: PMC4334774, DOI: 10.1200/jco.2014.57.6298.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorBreast NeoplasmsChemotherapy, AdjuvantDisease-Free SurvivalDNA, NeoplasmFemaleGene Expression Regulation, NeoplasticGenomicsHumansKaplan-Meier EstimateMiddle AgedMolecular Targeted TherapyProportional Hazards ModelsReceptor, ErbB-2TranscriptomeTrastuzumabConceptsRelapse-free survivalImmune function genesAdjuvant trastuzumab trialsArm BTrastuzumab trialsHazard ratioArm AHuman epidermal growth factor receptorClinicopathologic risk factorsProportional hazard ratiosEpidermal growth factor receptorGrowth factor receptorAdjuvant trastuzumabC patientsCombination chemotherapyClinical outcomesRisk factorsBreast cancerPatientsTrastuzumabPredictive signatureFunction genesChemotherapyGene enrichmentFactor receptor
2014
Adjuvant Chemotherapy in Breast Cancer
Lim E, Goel S, Winer E. Adjuvant Chemotherapy in Breast Cancer. 2014, 335-351. DOI: 10.1007/978-1-4939-1145-5_23.Peer-Reviewed Original ResearchAdjuvant chemotherapyAdjuvant chemotherapy regimenAdjuvant systemic therapyAdjuvant combination chemotherapyBreast cancer recurrenceYears of ageChemotherapy regimenPrognostic determinantsSystemic therapyCombination chemotherapyClinicians' estimationTumor stagePatient prognosisPatient outcomesCancer recurrenceBreast cancerMortality rateClinical practiceTumor biologyClinical settingChemotherapyBiological rationalePrognosisRecurrenceSignificant reduction
2006
Cancer and Leukemia Group B Breast Committee: Decades of Progress and Plans for the Future
Hudis CA, Winer EP. Cancer and Leukemia Group B Breast Committee: Decades of Progress and Plans for the Future. Clinical Cancer Research 2006, 12: 3576s-3580s. PMID: 16740788, DOI: 10.1158/1078-0432.ccr-06-9016.Peer-Reviewed Original Research
2003
Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741.
Citron ML, Berry DA, Cirrincione C, Hudis C, Winer EP, Gradishar WJ, Davidson NE, Martino S, Livingston R, Ingle JN, Perez EA, Carpenter J, Hurd D, Holland JF, Smith BL, Sartor CI, Leung EH, Abrams J, Schilsky RL, Muss HB, Norton L. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. Journal Of Clinical Oncology 2003, 21: 1431-9. PMID: 12668651, DOI: 10.1200/jco.2003.09.081.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsChemotherapy, AdjuvantCyclophosphamideDoxorubicinDrug Administration ScheduleFemaleFilgrastimGranulocyte Colony-Stimulating FactorHumansMiddle AgedMultivariate AnalysisPaclitaxelProportional Hazards ModelsRecombinant ProteinsSurvival AnalysisTreatment OutcomeConceptsOverall survivalDose-dense regimensBreast cancerAxillary node-positive breast cancerNode-positive primary breast cancerNode-positive breast cancerConcurrent combination chemotherapyDose-dense treatmentProtocol-specified analysisPostoperative adjuvant treatmentPrimary end pointPrimary breast cancerDose densityAdjuvant chemotherapyConcurrent chemotherapyAdjuvant treatmentSequential chemotherapySevere neutropeniaCombination chemotherapyClinical outcomesFemale patientsTreatment failureSequential doxorubicinConcurrent doxorubicinChemotherapy
1999
Phase I study of Doxil and vinorelbine in metastatic breast cancer
Burstein HJ, Ramirez MJ, Petros WP, Clarke KD, Warmuth MA, Marcom PK, Matulonis UA, Parker LM, Harris LN, Winer EP. Phase I study of Doxil and vinorelbine in metastatic breast cancer. Annals Of Oncology 1999, 10: 1113-1116. PMID: 10572612, DOI: 10.1023/a:1008323200102.Peer-Reviewed Original ResearchConceptsMetastatic breast cancerM2 days 1Breast cancerDay 1Grade 2 cardiac toxicityPrior anthracycline-based chemotherapyAnthracycline-based chemotherapyPhase II studyFirst treatment cyclePhase I studiesDose escalation schemeFavorable toxicity profilePharmacokinetic studyActive chemotherapeutic agentsHigher doxorubicin concentrationsDoxil administrationVinorelbine administrationSignificant nauseaII studySevere neutropeniaCombination chemotherapyCardiac toxicityCombination therapyEscalation schemeI studiesSafety and efficacy of using a single agent or a phase II agent before instituting standard combination chemotherapy in previously untreated metastatic breast cancer patients: report of a randomized study--Cancer and Leukemia Group B 8642.
Costanza M, Weiss R, Henderson I, Norton L, Berry D, Cirrincione C, Winer E, Wood W, Frei III E, McIntyre O, Schilsky R. Safety and efficacy of using a single agent or a phase II agent before instituting standard combination chemotherapy in previously untreated metastatic breast cancer patients: report of a randomized study--Cancer and Leukemia Group B 8642. Journal Of Clinical Oncology 1999, 17: 1397-406. PMID: 10334524, DOI: 10.1200/jco.1999.17.5.1397.Peer-Reviewed Original ResearchMeSH KeywordsAdenineAdultAgedAminoglycosidesAnalysis of VarianceAnti-Bacterial AgentsAntineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsCarboplatinCyclophosphamideDoxorubicinFemaleFluorouracilFollow-Up StudiesHumansImidesIsoquinolinesMelphalanMiddle AgedNaphthalimidesNeoplasm StagingOrganophosphonatesProspective StudiesSurvival AnalysisTrimetrexateConceptsPhase II agentMetastatic breast cancer patientsStandard combination chemotherapyMetastatic breast cancerBreast cancer patientsSingle agentResponse rateCombination chemotherapyCancer patientsBreast cancerUntreated metastatic breast cancer patientsMeasurable metastatic breast cancerRandomized phase III trialPhase III trialsDuration of responseSingle-agent drugsTreatment of patientsCumulative response rateSuggestion of benefitLow response rateImmediate chemotherapyIII trialsMetastatic diseaseVisceral diseaseRandomized study
1990
Improved survival in advanced Hodgkin's disease with the use of combined modality therapy
Brizel D, Winer E, Prosnitz L, Scott J, Crawford J, Moore J, Gockerman J. Improved survival in advanced Hodgkin's disease with the use of combined modality therapy. International Journal Of Radiation Oncology • Biology • Physics 1990, 19: 535-542. PMID: 2211201, DOI: 10.1016/0360-3016(90)90478-3.Peer-Reviewed Original ResearchConceptsSoutheastern Cancer Study GroupAdvanced Hodgkin's diseaseModality therapyTherapy patientsHodgkin's diseaseSoutheastern Cancer Study Group trialTen-year actuarial survivalInduction combination chemotherapyCancer Study GroupActuarial freedomActuarial survivalConsolidation radiotherapyAlone patientsPartial responseCombination chemotherapyInitial diagnosisChemotherapy patientsAcute leukemiaStudy groupGroup trialsChemotherapyPatientsMulti-variate analysisTherapyRelapse